Liver Cancer Diagnostic Tests – Medical Devices Pipeline Assessment, 2020

Liver Cancer Diagnostic Tests include assays of mostly antibodies released in response to a liver cancer and cancer-causing proteins. GlobalData's Medical Devices sector report, “Liver Cancer Diagnostic Tests – Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Liver Cancer Diagnostic Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

The Liver Cancer Diagnostic Tests Pipeline Assessment report provides key information and data related to:

Extensive coverage of the Liver Cancer Diagnostic Tests under development

Review details of major pipeline products which include product description, licensing and collaboration details and other developmental activities including pipeline territories, regulatory paths and estimated approval dates

Reviews of major players involved in the pipeline product development.

Provides key clinical trial data related to ongoing clinical trials such as trial phase, trial status, trial start and end dates, and, the number of trials of the major Liver Cancer Diagnostic Tests pipeline products.

Review of Recent Developments in the segment / industry

The Liver Cancer Diagnostic Tests Pipeline Assessment report enables you to:

Access significant competitor information, analysis, and insights to improve your R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of Glaucoma Drainage Device sunder development

Formulate market-entry and market expansion strategies

Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

The major companies covered in the “Liver Cancer Diagnostic Tests- Medical Devices Pipeline Assessment, 2020” report:

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

The GlobalData Differentiation

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

The data and analysis within this report are driven by GlobalData Medical Intelligence Center (GDMIC) database. GDMIC gives you the key information required to drive sales, investment and deal-making activity in your business. It includes the following:

• 15,000+ data tables showing market size across more than 780 medical equipment segments and 39 countries, from 2015 and forecast to 2025

• 6,700+ industry-leading analysis reports covering sector reports, medipoint reports, country analysis, expert insights and industry analysis (devices and procedures) reports

• 64,000+ medical equipment company profiles

• 5,600+ company profiles of medical equipment manufacturers in China and India

• 2,200+ company profiles of medical equipment manufacturers in Japan

• 1,200+ companies’ revenue splits and market shares

• 1,600+ quarterly and annual medical equipment company financials

• 850+ medical equipment company SWOTs

• 28,000+ pipeline product profiles

• 56,400+ marketed product profiles

• 47,000+ clinical trials

• 41,500+ trial investigators

• 7,000+ reports on companies with products in development

• 44,000+ deals in the medical equipment industry

• 1,100+ surgical and diagnostic procedures by therapy area

• 50+ key healthcare indicators by country

• 431,000+ Themes Content Items

• 600+ Influencers

• 1,900+ Analysts & Researchers

• 0.5m+ Community Members

• 141,000+ Macroeconomic Indicators

• 1,013,000+ City Indicators

For more information or to receive a free demonstration of the service, please visit:

https://medical.globaldata.com/home.aspx

Custom Requirements

Contact us to discuss the areas of your business where you need external input, and we will work with you to identify the strongest way forward to meet your needs.

Scope

Extensive coverage of the Liver Cancer Diagnostic Tests under development

The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

The report reviews the major players involved in the development of Liver Cancer Diagnostic Tests and list all their pipeline projects

The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

The report provides key clinical trial data of ongoing trials specific to pipeline products

Recent developments in the segment / industry

Reasons to buy

The report enables you to:

Formulate significant competitor information, analysis, and insights to improve R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of Liver Cancer Diagnostic Tests under development

Develop market-entry and market expansion strategies

Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

In-depth analysis of the product’s current stage of development, territory and estimated launch date

Companies mentioned

Abbott Diagnostics

Abcodia Ltd

AXO Science SAS

BioMark Technologies Inc

Bioprognos SL

China Sky One Medical Inc

Digna Biotech SL

Exact Sciences Corp

German Cancer Research Center

Glycotest Inc

Glympse Bio Inc

ImCare Biotech LLC

Imperial College London

IntegraGen SA

IPDx Immunoprofiling Diagnostics GmbH

JBS Science Inc

Matrix-Bio Inc

MDNA Life Sciences Inc

Medical University of South Carolina

Medical University of Vienna

Memorial Sloan Kettering Cancer Center

NanoString Technologies Inc

Northwestern University

Numares AG

Oncimmune (USA) LLC

Orion Genomics LLC

PleX Diagnostics Inc (Inactive)

ProMIS Neurosciences Inc

Proplex Technologies Llc

Proteome Sciences Plc

Roche Diagnostics International Ltd

University of Hong Kong

University of Louisville

University of Rochester

Ventana Medical Systems Inc

Viomics Inc.

XEPTAGEN SpA

Ymir Genomics LLC.

Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 7

2 Introduction 8

2.1 Liver Cancer Overview 8

3 Products under Development 9

3.1 Liver Cancer – Pipeline Products by Stage of Development 9

3.2 Liver Cancer – Pipeline Products by Territory 10

3.3 Liver Cancer – Pipeline Products by Regulatory Path 11

3.4 Liver Cancer – Pipeline Products by Estimated Approval Date 12

3.5 Liver Cancer – Ongoing Clinical Trials 13

4 Liver Cancer – Pipeline Products under Development by Companies 14

4.1 Liver Cancer Companies – Pipeline Products by Stage of Development 14

4.2 Liver Cancer – Pipeline Products by Stage of Development 16

5 Liver Cancer Companies and Product Overview 18

5.1 Abbott Diagnostics Company Overview 18

5.1.1 Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 18

5.2 Abcodia Ltd Company Overview 23

5.2.1 Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview 23

5.3 AXO Science SAS Company Overview 24

5.3.1 AXO Science SAS Pipeline Products & Ongoing Clinical Trials Overview 24

5.4 BioMark Technologies Inc Company Overview 27

5.4.1 BioMark Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 27

5.5 Bioprognos SL Company Overview 28

5.5.1 Bioprognos SL Pipeline Products & Ongoing Clinical Trials Overview 28

5.6 China Sky One Medical Inc Company Overview 29

5.6.1 China Sky One Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 29

5.7 Digna Biotech SL Company Overview 30

5.7.1 Digna Biotech SL Pipeline Products & Ongoing Clinical Trials Overview 30

5.8 Exact Sciences Corp Company Overview 32

5.8.1 Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview 32

5.9 German Cancer Research Center Company Overview 34

5.9.1 German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 34

5.10 Glycotest Inc Company Overview 35

5.10.1 Glycotest Inc Pipeline Products & Ongoing Clinical Trials Overview 35

5.11 Glympse Bio Inc Company Overview 38

5.11.1 Glympse Bio Inc Pipeline Products & Ongoing Clinical Trials Overview 38

5.12 ImCare Biotech LLC Company Overview 39

5.12.1 ImCare Biotech LLC Pipeline Products & Ongoing Clinical Trials Overview 39

5.13 Imperial College London Company Overview 40

5.13.1 Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 40

5.14 IntegraGen SA Company Overview 41

5.14.1 IntegraGen SA Pipeline Products & Ongoing Clinical Trials Overview 41

5.15 IPDx Immunoprofiling Diagnostics GmbH Company Overview 42

5.15.1 IPDx Immunoprofiling Diagnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview 42

5.16 JBS Science Inc Company Overview 43

5.16.1 JBS Science Inc Pipeline Products & Ongoing Clinical Trials Overview 43

5.17 Matrix-Bio Inc Company Overview 44

5.17.1 Matrix-Bio Inc Pipeline Products & Ongoing Clinical Trials Overview 44

5.18 MDNA Life Sciences Inc Company Overview 46

5.18.1 MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 46

5.19 Medical University of South Carolina Company Overview 47

5.19.1 Medical University of South Carolina Pipeline Products & Ongoing Clinical Trials Overview 47

5.20 Medical University of Vienna Company Overview 48

5.20.1 Medical University of Vienna Pipeline Products & Ongoing Clinical Trials Overview 48

5.21 Memorial Sloan Kettering Cancer Center Company Overview 49

5.21.1 Memorial Sloan Kettering Cancer Center Pipeline Products & Ongoing Clinical Trials Overview 49

5.22 NanoString Technologies Inc Company Overview 50

5.22.1 NanoString Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 50

5.23 Northwestern University Company Overview 51

5.23.1 Northwestern University Pipeline Products & Ongoing Clinical Trials Overview 51

5.24 Numares AG Company Overview 52

5.24.1 Numares AG Pipeline Products & Ongoing Clinical Trials Overview 52

5.25 Oncimmune (USA) LLC Company Overview 53

5.25.1 Oncimmune (USA) LLC Pipeline Products & Ongoing Clinical Trials Overview 53

5.26 Orion Genomics LLC Company Overview 54

5.26.1 Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview 54

5.27 PleX Diagnostics Inc (Inactive) Company Overview 55

5.27.1 PleX Diagnostics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 55

5.28 ProMIS Neurosciences Inc Company Overview 56

5.28.1 ProMIS Neurosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 56

5.29 Proplex Technologies Llc Company Overview 57

5.29.1 Proplex Technologies Llc Pipeline Products & Ongoing Clinical Trials Overview 57

5.30 Proteome Sciences Plc Company Overview 58

5.30.1 Proteome Sciences Plc Pipeline Products & Ongoing Clinical Trials Overview 58

5.31 Roche Diagnostics International Ltd Company Overview 59

5.31.1 Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 59

5.32 University of Hong Kong Company Overview 60

5.32.1 University of Hong Kong Pipeline Products & Ongoing Clinical Trials Overview 60

5.33 University of Louisville Company Overview 62

5.33.1 University of Louisville Pipeline Products & Ongoing Clinical Trials Overview 62

5.34 University of Rochester Company Overview 63

5.34.1 University of Rochester Pipeline Products & Ongoing Clinical Trials Overview 63

5.35 Ventana Medical Systems Inc Company Overview 64

5.35.1 Ventana Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 64

5.36 Viomics Inc. Company Overview 65

5.36.1 Viomics Inc. Pipeline Products & Ongoing Clinical Trials Overview 65

5.37 XEPTAGEN SpA Company Overview 66

5.37.1 XEPTAGEN SpA Pipeline Products & Ongoing Clinical Trials Overview 66

5.38 Ymir Genomics LLC. Company Overview 70

5.38.1 Ymir Genomics LLC. Pipeline Products & Ongoing Clinical Trials Overview 70

6 Liver Cancer- Recent Developments 71

6.1 Sep 30, 2020: Skoltech scientists discovered a new biomarker for liver cancer diagnosis 71

6.2 Jul 30, 2020: Blueprint Medicines reports second quarter 2020 financial results 71

6.3 Jun 24, 2020: Novel radiotracer proves advantageous for imaging neuroendocrine tumor patients with liver-dominant disease 74

6.4 Jun 15, 2020: Study demonstrates feasibility of hologram technology in liver tumor ablation 74

6.5 Jun 02, 2020: Pfizer establishes new program to support continued biotechnology innovation 75

6.6 May 12, 2020: National Cancer Institute renews Jackson Laboratory’s Cancer Center Designation 76

6.7 Feb 27, 2020: James Quincey elected to Pfizer’s board of directors 77

6.8 Feb 14, 2020: Pfizer: Appointment of Mr. Samir Kazi as an executive director 77

6.9 Feb 14, 2020: Pfizer: Resignation of Mr. Vivek Dhariwal 78

6.10 Feb 13, 2020: Blueprint Medicines reports fourth quarter and full year 2019 financial results 78

6.11 Jan 28, 2020: Pfizer reports fourth-quarter and full-year 2019 results 80

6.12 Jan 27, 2020: PerkinElmer announces financial results for the fourth quarter 87

6.13 Jan 13, 2020: Blueprint Medicines announces 2020 corporate goals 89

6.14 Jan 02, 2020: Pfizer, Sanofi and GlaxoSmithKline plan to increase US drug prices in 2020 90

6.15 Dec 18, 2019: Pfizer and Mylan announce two future Viatris board members 90

6.16 Dec 16, 2019: Pfizer declares first-quarter 2020 dividend and announces upcoming investor day to highlight strength of innovative R&D pipeline 91

7 Appendix 92

7.1 Methodology 92

7.2 About GlobalData 96

7.3 Contact Us 96

List of Tables

Table 1: Liver Cancer – Pipeline Products by Stage of Development 9

Table 2: Liver Cancer – Pipeline Products by Territory 10

Table 3: Liver Cancer – Pipeline Products by Regulatory Path 11

Table 4: Liver Cancer – Pipeline Products by Estimated Approval Date 12

Table 5: Liver Cancer – Ongoing Clinical Trials 13

Table 6: Liver Cancer Companies – Pipeline Products by Stage of Development 14

Table 7: Liver Cancer – Pipeline Products by Stage of Development 16

Table 8: Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 18

Table 9: ARCHITECT c16000 System – PIVKA Assay – Product Status 18

Table 10: ARCHITECT c16000 System – PIVKA Assay – Product Description 19

Table 11: ARCHITECT c4000 System – PIVKA Assay – Product Status 19

Table 12: ARCHITECT c4000 System – PIVKA Assay – Product Description 19

Table 13: ARCHITECT c8000 System – PIVKA Assay – Product Status 20

Table 14: ARCHITECT c8000 System – PIVKA Assay – Product Description 20

Table 15: ARCHITECT ci16200 Integrated System – PIVKA Assay – Product Status 20

Table 16: ARCHITECT ci16200 Integrated System – PIVKA Assay – Product Description 20

Table 17: ARCHITECT ci4100 Integrated System – PIVKA Assay – Product Status 21

Table 18: ARCHITECT ci4100 Integrated System – PIVKA Assay – Product Description 21

Table 19: ARCHITECT ci8200 Integrated System – PIVKA Assay – Product Status 21

Table 20: ARCHITECT ci8200 Integrated System – PIVKA Assay – Product Description 22

Table 21: ARCHITECT i4000SR System – PIVKA II Assay – Product Status 22

Table 22: ARCHITECT i4000SR System – PIVKA II Assay – Product Description 22

Table 23: Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview 23

Table 24: Biomarker Test – Liver Cancer – Product Status 23

Table 25: Biomarker Test – Liver Cancer – Product Description 23

Table 26: AXO Science SAS Pipeline Products & Ongoing Clinical Trials Overview 24

Table 27: Multiplexed Detection – Des-Carboxy Prothrombin – Product Status 24

Table 28: Multiplexed Detection – Des-Carboxy Prothrombin – Product Description 24

Table 29: Multiplexed Detection – Matrix metalloproteinase 1 – Product Status 25

Table 30: Multiplexed Detection – Matrix metalloproteinase 1 – Product Description 25

Table 31: Multiplexed Detection – Procollagen type III N-terminal peptide – Product Status 25

Table 32: Multiplexed Detection – Procollagen type III N-terminal peptide – Product Description 26

Table 33: BioMark Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 27

Table 34: Biomarker Assay – Hepatocellular Cancer – Product Status 27

Table 35: Biomarker Assay – Hepatocellular Cancer – Product Description 27

Table 36: Bioprognos SL Pipeline Products & Ongoing Clinical Trials Overview 28

Table 37: MBDAA Liver Cancer Test – Product Status 28

Table 38: MBDAA Liver Cancer Test – Product Description 28

Table 39: China Sky One Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 29

Table 40: Diagnostic Kit – Liver Cancer – Product Status 29

Table 41: Diagnostic Kit – Liver Cancer – Product Description 29

Table 42: Digna Biotech SL Pipeline Products & Ongoing Clinical Trials Overview 30

Table 43: HCC Molecular Marker Assay – Product Status 30

Table 44: HCC Molecular Marker Assay – Product Description 30

Table 45: Oxidated APO-A1 Assay – Product Status 31

Table 46: Oxidated APO-A1 Assay – Product Description 31

Table 47: Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview 32

Table 48: DNA Biomarkers – Hepatocellular Carcinoma – Product Status 32

Table 49: DNA Biomarkers – Hepatocellular Carcinoma – Product Description 32

Table 50: Liquid Biopsy Test – Liver Cancer – Product Status 33

Table 51: Liquid Biopsy Test – Liver Cancer – Product Description 33

Table 52: German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 34

Table 53: RAGE Based Diagnostic Assay – Liver Cancer – Product Status 34

Table 54: RAGE Based Diagnostic Assay – Liver Cancer – Product Description 34

Table 55: Glycotest Inc Pipeline Products & Ongoing Clinical Trials Overview 35

Table 56: HCC Panel – Product Status 35

Table 57: HCC Panel – Product Description 35

Table 58: Glycotest Inc – Ongoing Clinical Trials Overview 36

Table 59: HCC Panel – Case-control Study of the Glycotest HCC Panel Versus AFP for the Detection of Early-stage Hepatocellular Carcinoma 37

Table 60: Glympse Bio Inc Pipeline Products & Ongoing Clinical Trials Overview 38

Table 61: Ultrasensitive Diagnostic Test – HCC – Product Status 38

Table 62: Ultrasensitive Diagnostic Test – HCC – Product Description 38

Table 63: ImCare Biotech LLC Pipeline Products & Ongoing Clinical Trials Overview 39

Table 64: Seravue Diagnostic Kit – Product Status 39

Table 65: Seravue Diagnostic Kit – Product Description 39

Table 66: Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 40

Table 67: Diagnostic Assay – HCC – Product Status 40

Table 68: Diagnostic Assay – HCC – Product Description 40

Table 69: IntegraGen SA Pipeline Products & Ongoing Clinical Trials Overview 41

Table 70: Diagnostic Test – Hepatocellular Carcinoma – Product Status 41

Table 71: Diagnostic Test – Hepatocellular Carcinoma – Product Description 41

Table 72: IPDx Immunoprofiling Diagnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview 42

Table 73: Diagnostic Test – Liver Cancer – Product Status 42

Table 74: Diagnostic Test – Liver Cancer – Product Description 42

Table 75: JBS Science Inc Pipeline Products & Ongoing Clinical Trials Overview 43

Table 76: JBS HCC Urine DNA Screening Test – Product Status 43

Table 77: JBS HCC Urine DNA Screening Test – Product Description 43

Table 78: Matrix-Bio Inc Pipeline Products & Ongoing Clinical Trials Overview 44

Table 79: VeraMarker LCS (Liver Cancer Screening) Test – Product Status 44

Table 80: VeraMarker LCS (Liver Cancer Screening) Test – Product Description 44

Table 81: VeraMarker Liver Cancer Screening Test – Hepatitis – Product Status 45

Table 82: VeraMarker Liver Cancer Screening Test – Hepatitis – Product Description 45

Table 83: MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 46

Table 84: Mitomic Liver Test – Product Status 46

Table 85: Mitomic Liver Test – Product Description 46

Table 86: Medical University of South Carolina Pipeline Products & Ongoing Clinical Trials Overview 47

Table 87: Glycan-Based Biomarker Assay – Liver Cancer – Product Status 47

Table 88: Glycan-Based Biomarker Assay – Liver Cancer – Product Description 47

Table 89: Medical University of Vienna Pipeline Products & Ongoing Clinical Trials Overview 48

Table 90: sAXL Biomarker Test – Hepatocellular Carcinoma – Product Status 48

Table 91: sAXL Biomarker Test – Hepatocellular Carcinoma – Product Description 48

Table 92: Memorial Sloan Kettering Cancer Center Pipeline Products & Ongoing Clinical Trials Overview 49

Table 93: Biomarker Test – Hepatocellular Carcinoma – Product Status 49

Table 94: Biomarker Test – Hepatocellular Carcinoma – Product Description 49

Table 95: NanoString Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 50

Table 96: In Vitro Diagnostic Assay – HCC Gene Signature – Product Status 50

Table 97: In Vitro Diagnostic Assay – HCC Gene Signature – Product Description 50

Table 98: Northwestern University Pipeline Products & Ongoing Clinical Trials Overview 51

Table 99: Blood Test – Liver Cancer – Product Status 51

Table 100: Blood Test – Liver Cancer – Product Description 51

Table 101: Numares AG Pipeline Products & Ongoing Clinical Trials Overview 52

Table 102: Diagnostic Test – Liver Cancer – Product Status 52

Table 103: Diagnostic Test – Liver Cancer – Product Description 52

Table 104: Oncimmune (USA) LLC Pipeline Products & Ongoing Clinical Trials Overview 53

Table 105: EarlyCDT – Liver Cancer Kit – Product Status 53

Table 106: EarlyCDT – Liver Cancer Kit – Product Description 53

Table 107: Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview 54

Table 108: Diagnostic Assay – Liver Cancer – Product Status 54

Table 109: Diagnostic Assay – Liver Cancer – Product Description 54

Table 110: PleX Diagnostics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 55

Table 111: HCCpleX – Product Status 55

Table 112: HCCpleX – Product Description 55

Table 113: ProMIS Neurosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 56

Table 114: Screening Test – Liver Cancer – Product Status 56

Table 115: Screening Test – Liver Cancer – Product Description 56

Table 116: Proplex Technologies Llc Pipeline Products & Ongoing Clinical Trials Overview 57

Table 117: Biomarker Diagnostic Test – Liver Cancer – Product Status 57

Table 118: Biomarker Diagnostic Test – Liver Cancer – Product Description 57

Table 119: Proteome Sciences Plc Pipeline Products & Ongoing Clinical Trials Overview 58

Table 120: Biomarker Assay – Liver Cancer – Product Status 58

Table 121: Biomarker Assay – Liver Cancer – Product Description 58

Table 122: Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 59

Table 123: Cobas 8000 Analyzer Series With e 801 Module – PIVKA Assay – Product Status 59

Table 124: Cobas 8000 Analyzer Series With e 801 Module – PIVKA Assay – Product Description 59

Table 125: University of Hong Kong Pipeline Products & Ongoing Clinical Trials Overview 60

Table 126: Annexin Biomarker Test – Hepatocellular Carcinoma – Product Status 60

Table 127: Annexin Biomarker Test – Hepatocellular Carcinoma – Product Description 60

Table 128: Granulin-Epithelin Precursor Test – Hepatocellular Carcinoma – Product Status 61

Table 129: Granulin-Epithelin Precursor Test – Hepatocellular Carcinoma – Product Description 61

Table 130: University of Louisville Pipeline Products & Ongoing Clinical Trials Overview 62

Table 131: Diagnostic Test – Hepatocellular Carcinoma – Product Status 62

Table 132: Diagnostic Test – Hepatocellular Carcinoma – Product Description 62

Table 133: University of Rochester Pipeline Products & Ongoing Clinical Trials Overview 63

Table 134: Biomarker Test – HCC – Product Status 63

Table 135: Biomarker Test – HCC – Product Description 63

Table 136: Ventana Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 64

Table 137: BLU-554 Companion Diagnostic Assay – Hepatocellular Carcinoma – Product Status 64

Table 138: BLU-554 Companion Diagnostic Assay – Hepatocellular Carcinoma – Product Description 64

Table 139: Viomics Inc. Pipeline Products & Ongoing Clinical Trials Overview 65

Table 140: Diagnostic Assay – Liver Cancer – Product Status 65

Table 141: Diagnostic Assay – Liver Cancer – Product Description 65

Table 142: XEPTAGEN SpA Pipeline Products & Ongoing Clinical Trials Overview 66

Table 143: DCP-IgM Kit – Liver Cancer – Product Status 66

Table 144: DCP-IgM Kit – Liver Cancer – Product Description 66

Table 145: GPC3-IgM Kit – Liver Cancer – Product Status 67

Table 146: GPC3-IgM Kit – Liver Cancer – Product Description 67

Table 147: Osteopontin-IgM Kit – Liver Cancer – Product Status 67

Table 148: Osteopontin-IgM Kit – Liver Cancer – Product Description 68

Table 149: Survivin-IgM Kit – Liver Cancer – Product Status 68

Table 150: Survivin-IgM Kit – Liver Cancer – Product Description 68

Table 151: VEGF-IgM Kit – Liver Cancer – Product Status 69

Table 152: VEGF-IgM Kit – Liver Cancer – Product Description 69

Table 153: Ymir Genomics LLC. Pipeline Products & Ongoing Clinical Trials Overview 70

Table 154: Diagnostic Assay – Hepatocellular Carcinoma – Product Status 70

Table 155: Diagnostic Assay – Hepatocellular Carcinoma – Product Description 70

Table 156: Glossary 95

List of Figures

Figure 1: Liver Cancer – Pipeline Products by Stage of Development 9

Figure 2: Liver Cancer – Pipeline Products by Territory 10

Figure 3: Liver Cancer – Pipeline Products by Regulatory Path 11

Figure 4: Liver Cancer – Pipeline Products by Estimated Approval Date 12

Figure 5: Liver Cancer – Ongoing Clinical Trials 13

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports